NZ299145A

NZ299145A - 3,5-dicarboxyl-substituted 4h-pyran derivatives

Info

Publication number: NZ299145A
Application number: NZ299145A
Authority: NZ
Inventors: Klaus Urbahns; Hans-Georg Heine; Bodo Junge; Frank Mauler; Thomas Glaser; Reilinde Wittka; Vry Jean-Marie-Viktor De
Original assignee: Bayer Ag
Priority date: 1995-08-14
Filing date: 1996-08-09
Publication date: 1998-03-25
Also published as: DE19529858A1; SK105596A3; HUP9602220A2; ATE190611T1; AU6193196A; HU9602220D0; IL119054A0; GR3033357T3; NO963374L; PT758648E; HUP9602220A3; CZ239496A3; RU2164915C2; DK0758648T3; SI0758648T1; NO963374D0; ZA966832B; US5760073A; IL119054A; JPH0959271A

Abstract

Substd. 4H-pyran derivs. of formula (I) and their salts are new: A = 3-6C cycloalkyl; or 1-8C alkyl; or 6-10C aryl or pyridyl opt. substd. up to three times by NO2, OH, COOH, CN, 6-10C aryl, halo, 3-6C cycloalkyl, CF3 or 1-6C alkyl, 1-6C alkoxycarbonyl, 1-6C alkylthio or 1-6C alkoxy or a group -O-CO-R5; R5 = 1-6C alkyl; R1, R2 = H, NH2, 1-8C alkyl, 1-8C alkoxy or 1-8C alkylamino; R3, R4 = 1-6C alkyl or 1-6C acyl. The following cpds. are excluded : 3,5-diacetyl-2,4,6-trimethyl-4H-pyran (Ia), 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran (Ib) and 3,5-diethoxycarbonyl-2,4,6-trimethyl-4H-pyran (Ic).

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number £99145 New Zealand No. 299145 International No. PCT/ TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: 14.08.1995; Complete Specification Filed: 09.08.1996 Classification:^) C07D309/32; C07D405/04; A61K31/35.44 Publication date: 25 March 1998 Journal No.: 1426 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION Title of Invention: Substituted 4H-pyrans Name, address and nationality of applicant(s) as in international application form: BAYER AKTIENGESELLSCHAFT, a German company of D-51368 Leverkusen, Federal Republic of Germany 29 914 5 Patents Form 5 N.Z. No. NEW ZEALAND Patents Act 1953 COMPLETE SPECIFICATION SUBSTITUTED 4H-PYRANS We, BAYER AKTIENGESELLSCHAFT, a Company registered under the laws of the Federal Republic of Germany of, D-51368 Leverkusen, Federal Republic of Germany, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- I^WSjoFFiCEj J 9 AUG 1996 R^CL;Vr;o""~~ -1 - (Followed by 1A) La A 31 16*1 rmumi Cnmniii,& /K/wn/BP - 1A Substituted 4H-nvrans The present invention relates to substituted 4H-pyrans, to processes for their preparation and to their use as medicaments, especially as cerebrally active agents. The publication J. Org. Chem. (1969), 34 (10), 3169-74 discloses some substituted 4H-5 pyrans. The present invention now relates to substituted 4H-pyrans of the general formula (I) A in which A represents cycloalkyl having 3 to 6 carbon atoms or 10 represents straight-chain or branched alkyl having up to 8 carbon atoms, or represents aryl having 6 to 10 carbon atoms or represents pyridyl, which are optionally substituted up to 3 times by identical or different substituents consisting of nitro, hydroxyl, carboxyl, cyano, aryl having 6 to 10 carbon atoms, halogen, cycloalkyl having 3 to 6 carbon atoms, trifluoromethyl or by 15 straight-chain or branched alkyl, alkoxycarbonyl, alkylthio or alkoxy having in each case up to 6 carbon atoms, or by a group of the formula -0-C0-Rs, in which 299145 R5 denotes straight-chain or branched alkyl having up to 6 carbon atoms, R1 and R2 are identical or different and represent hydrogen, amino or represent straight-chain or branched alkyl, alkoxy or alkylamino having in each case up to 8 carbon atoms, R3 and R4 are identical or different and represent straight-chain or branched alkyl or acyl having in each case up to 6 carbon atoms, and salts thereof, with the exception of 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and 3,5-diethoxycarbonyl~2,4,6-trimethyl-4H-pyran. Within the scope of the invention, physiologically acceptable salts are preferred. Physiologically acceptable salts are, in general, salts of the compounds according to the invention with inorganic or organic acids. Preferred salts are those with inorganic acids, for example hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid, or salts with organic carboxylic or sulphonic acids, for example acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulphonic acid, ethanesulphonic acid, phenylsulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid. The compounds according to the invention can exist in stereoisomeric forms whose relationship to one another is either that of image to mirror image (enantiomers) or not (diastereomers). The invention relates both to the isomers and the racemic forms, and also to the diastereomer mixtures. Like these diastereomers, the racemic forms can also be resolved into the stereoisomerically uniform constituents in a known manner. Preference is given to compounds of the general formula (I) in which A represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, or represents straight-chain or branched alkyl having up to 6 carbon-atoms, or represents phenyl, naphthyl or pyridyl which are optionally substituted up to 3 times by identical or different substituents consisting of nitro, cyano, fluoro, chloro, bromo, iodo, phenyl, naphthyl, trifluoromethyl, hydroxyl, carboxyl, cyclopropyl, cyclopentyl, cyclohexyl or by straight-chain or branched alkyl, alkoxycarbonyl, alkylthio or alkoxy having in each case up to 4 carbon atoms, or by a group of the formula -O-CO-R5 in which R5 denotes straight-chain or branched alkyl having up to 4 carbon atoms, R1 and R2 are identical or different and represent hydrogen, amino or represent straight-chain or branched alkyl, alkoxy or alkylamino having in each case up to 6 carbon atoms, R3 and R4 are identical or different and represent straight-chain or branched alkyl or acyl having in each case up to 4 carbon atoms, and salts thereof, with the exception of 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and 3,5-diethoxycarbonyl-2,4,6-trimethyl-4H-pyran. Particular preference is given to compounds of the general formula (I) in which V iA ^ ■161 rofoiaw CeuMti'iiiis 29 9145 - 4 - A represents cyclopropyl, cyclohexyl or represents straight-chain or branched alkyl having up to 4 carbon atoms, or represents naphthyl or phenyl which are optionally substituted up to 3 times by identical or different substituents consisting of nitro, cyano, fluoro, chloro, 5 bromo, iodo, phenyl, naphthyl, hydroxyl, carboxyl, cyclopropyl, cyclopentyl, cyclohexyl, trifluoromethyl, or by straight-chain or branched alkyl, alkoxycarbonyl, alkylthio or alkoxy having in each case up to 4 carbon atoms, or by a group of the formula -O-CO-R5 in which 10 R5 denotes straight-chain or branched alkyl having up to 4 carbon atoms, R1 and R2 are identical or different and represent hydrogen, amino or represent straight-chain or branched alkyl, alkoxy or alkylamino having in each case up to 4 carbon atoms, R3 and R4 are identical or different and 15 represent straight-chain or branched alkyl or acyl having in each case up to 4 carbon atoms, and salts thereof, with the exception of 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and 3,5-diethoxycarbonyl-2,4,6-trimethyl-4H-pyran. 20 Moreover, a process has been found for the preparation of the compounds of the general formula (I) according to the invention, characterized in that [A] aldehydes of the general formula (II) 29 9 A. Comitates -5 - A-CHO (II) in which A has the meaning given above are reacted with compounds of the general formula (III) O O (HI) in which R6 embraces the meanings of R1 and R2 given above in each case and R7 embraces the meanings of R3 and R4 given above, 10 or [B] ylidene compounds of the general formula (IV) R2-OC (IV) R3 in which A, R and R3 have the meanings given above, 29914 - 6 - are reacted with compounds of the general formula (Ilia) or (IHb) O O O XAr, <w> D o o (IHb) R ,4 in which Rl and R4 have the meanings given above and D together with the CO group, forms an electron-attracting, activated radical, with D representing for example hydrogen, trifluoromethyl, phenyl or C,-C4-alkyl, preferably methyl, in inert solvents in the presence of auxiliaries and/or in the presence of a dehydrating agent, and, in the case of the compounds of the general formula (I) in which R'/R2 represent amino and/or alkylamino, the corresponding acids are first of all prepared by hydrolysis from the esters, are converted into the carbonyl chlorides by transesterification, for example with thionyl chloride, and in a final step are reacted with ammonia or alkylamines. The processes according to the invention can be illustrated by way of example using the following formula scheme: HN^° cfav I 3IOUZ eHOzHO~ ^ ^OzHOEH eHOzOO^ ^ ^ ^OzOOcH HO + HOO O O 10 (I - L 9H66Z ^^.ry.r.r.j ..ay.™ j^.n f |f y Le_^_lLIM«Ea*»wn Countries. 3) O .A 2991 4) 5) - 8 H3C O O AA ,ch, + ZnCI, MeOOC COOMe H3C 0 CH3 CI "•i h3c' CI I /cf3 h3c I ^w1 co2ch3 NaOCH3 1 1 CH3OH h3c 0^ ch3 CI A. < 1) SOCI2 H,C I ij 2) NH3 "W 3 i o CF, CO-NH, Suitable solvents are all inert organic solvents which do not change under the reaction conditions. These include, preferably, ethers such as diethyl ether, dioxane, tetrahydrofiiran, glycol dimethyl ether or diethylene glycol dimethyl ether, ethyl acetate, or acetonitrile, or amides such as hexamethyl phosphoric triamide or - 9 - dimethylformamide, or halogenated hydrocarbons such as methylene chloride, carbon tetrachloride or hydrocarbons such as benzene or toluene, or pyridine, or carboxylic acids such as AcOH or CF3COOH. It is likewise possible to use mixtures of the solvents mentioned. Glacial acetic acid is preferred. 5 Suitable dehydrating agents are acid anhydrides and acid chlorides, such as acetic anhydride (Ac20), acetyl chloride (AcCl), POCl3, SOCl2, S02C12 or molecular sieves. Ac20 is preferred. The water of reaction can also be removed azeotropically. If enol acetates are incorporated by stirring, no dehydrating agent is necessary. Examples of suitable auxiliaries are TiCl4, SnCl4, BF3 x OEt2, Zn(OAc)2, LiC104 or 10 zinc chloride. Zinc chloride is preferred. The auxiliary is employed in a quantity of irom 0.1 mol to 5 mol, preferably from 1 mol to 2 mol, based in each case on 1 mol of the compounds of the general formulae (II) and (IV). The process is generally carried out in a temperature range from 0°C to 150°C, 15 preferably from 40°C to 80°C. The reactions can be carried out under atmospheric pressure, but also under elevated or reduced pressure (e.g. from 0.5 to 3 bar). They are generally carried out under atmospheric pressure. The compounds of the general formulae (II), (III), (Ilia), (Illb) and (IV) are known per 20 se or can be prepared by customary methods. Enantiomerically pure forms are obtained, for example, by using a customary method to separate diastereomer mixtures of the compounds of the genera formula (I) in which R1 represents an optically active ester radical, then either subjecting the diastereomers directly to transesterification, or first preparing the chiral carboxylic acids and then J1 1UI I01li.mil UUUUU1L9* Cfc ^ g fr* -10- preparing the enantiomerically pure compounds by esterification. The diastereomers are generally separated either by fractional crystallization, by column chromatography or by Craig partition. The decision as to which process is optimal must be decided from case to case; in some cases it is also expedient to use combinations of the individual methods. Separation by crystallization or Craig partition, or a combination of both methods, is particularly suitable. The enantiomerically pure compounds are also obtainable by chromatography of the racemic esters on chiral phases. The invention also relates to the use of the known compounds 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and 3,5-diethoxycarbonyl-2-4,6-trimethyl-4H-pyran and of the compounds according to the invention as medicaments, especially as cerebrally active medicaments. The known compounds and the compounds according to the invention of the general formula (I) display an unforeseeable, valuable spectrum of pharmacological action. They are modulators having selectivity for calcium-dependent and charybdotoxin-sensitive potassium channels (IK(Ca) channels), in particular of the central nervous system. On account of their pharmacological properties they can be employed for the preparation of medicaments, especially medicaments for the treatment of degenerative CNS disorders, for example in the case of occurrence of dementias such as multiinfarct dementia (MID), primary degenerative dementia (PDD), presenile and senile dementia in Alzheimer's disease, HIV dementia and other forms of dementia. They are additionally suitable for the treatment of Parkinson's disease or amyotrophic lateral sclerosis, and also multiple sclerosis. La-A 31 161 rai'iiiiiiu Cowntrios* - 11 - The active compounds are additionally suitable for the treatment of brain function disorders in old age, of organic brain syndrome (OBS) and of age-related memory disorders (age-associated memory impairment, AAMI). They are suitable for the prophylaxis and treatment and for the control of the sequelae 5 of cerebral circulatory disorders such as cerebral ischaemias, strokes, craniocerebral traumata and of subarachnoid haemorrhages. They are useful for the treatment of depressions and psychoses, e.g. schizophrenia. They are additionally suitable for the treatment of disorders of neuroendocrine secretion and of neurotransmitter secretion and health disorders connected therewith, such as 10 mania, alcoholism, drug abuse, dependence or abnormal eating behaviour. Other areas of application are the treatment of migraine, sleep disorders and neuropathies. They are, moreover, suitable as analgesics. The active compounds are suitable, furthermore, for the treatment of disorders of the immune system, in particular of T-lymphocyte proliferation, and for influencing the 15 smooth musculature, in particular of the uterus, urinary bladder and bronchial tract, and for the treatment of diseases connected therewith, for example asthma and urinary incontinence, and for the treatment of high blood pressure, arrhythmia, angina, diabetes and sickle-cell anaemia, cancer, restenosis, chronic obstructive pulmonary disease and edema. The present invention also includes pharmaceutical preparations which, in addition to 20 inert, non-toxic, pharmaceutical^ appropriate auxiliaries and excipients, contain one or more compounds of the general formula (I), or which consist of one or more active compounds of the formula (I), and processes for the production of these preparations. The active compounds of the formula (I) should be present in these preparations in a concentration of from 0.1 to 99.5% by weight, preferably from 0.5 to 95% by weight 25 of the overall mixture. In addition to the active compounds of the formula (I), the pharmaceutical preparations 299145 29 914 Lo A 31 4^>4£QieianJCewrt««6 - 12 - can also comprise other pharmaceutical active compounds. The abovementioned pharmaceutical preparations can be prepared in a customary manner by known methods, for example using the auxiliary(ies) or excipient(s). In general, it has proved advantageous to administer the active compound or 5 compounds of the formula (I) in total quantities of from about 0.01 to about 100 mg/kg, preferably in total quantities of from about 1 mg/kg to 50 mg/kg of body weight every 24 hours, if desired in the form of a plurality of individual doses, in order to achieve the desired result. However, if appropriate, it may be advantageous to depart from the quantities 10 mentioned, depending in fact on the nature and on the body weight of the subject treated, on the individual response to the medicament, on the nature and severity of the disorder, on the type of preparation and administration, and on the time or interval at which administration is made. Rubidium efflux from G-BUl glioma cells 15 The experiments were carried out with slight modifications in accordance with the method described by Tas et al. (Neurosci. Lett. 94, 279-284 (1988)), using rat C6-BU1 glioma cells. Detection is performed by atomic absorption spectroscopy. Examples Example 1 20 Dimethyl 4-(4-chlorophenyl)-2,6-diethyl-4H-pyran-3,5-dicarboxylate - 13 - CI h3c-o2c h3ch2c u ch2ch. co2ch3 7.0 g (0.05 mol) of 4-chlorobenzaldehyde, 15.6 g (0.12 mol) of methyl 3-oxovalerate and 6.8 g (0.05 mol) of anhydrous zinc chloride are dissolved with stirring in a mixture of 9.3 g of glacial acetic acid and 10.4 g of acetic anhydride, and the solution is then 5 left to stand at room temperature (20-25°C) for five weeks. The homogeneous solution is introduced into 100 g of ice and subjected to extraction with dichloromethane. The dichloromethane extracts are washed in succession with water, saturated sodium bicarbonate solution and water. The dichloromethane phase is dried over anhydrous sodium sulphate and filtered, the filtrate is evaporated in vacuo, and the residue 10 (20.3 g) is chromatographed over 600 g of silica gel using toluene/ethyl acetate (10:1). 2.7 g of a uniform colourless oil are obtained which is freed from solvent residues by bulb-tube distillation (200°C/0.01 mbar). Rf (toluene/ethyl acetate = 10:1): 0.52 'H-NMR (CDC13): 6 = 7.26-7.13 m (4, aromatic protons), 4.73 s (1, C4-H), 3.64 s (6, C3-COOCH3 and C5-COOCH3), 2.84 and 2.74 dddd, appears as a 12-line signal (4, C2-CH2- and C6-CH,)- and 1.90 ppm t (6, C2-CH2-CH3 and C6-CH2-CH3). C19H21C10 15 (364.8) Calc. C: 62.55%; H: 5.80% Found C: 62.20%; H: 5.86% Example 2 20 3,5-Diacetyl-4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran - 14 - CI 7.0 g (0.05 mol) of 4-chlorobenzaldehyde, 12.0 g (0.12 mol) of pentane-2,4-dione and 6.8 g (0.05 mol) of anhydrous zinc chloride are left to stand at room temperature for 3 weeks in a mixture of 8.9 ml of glacial acetic acid and 9.6 ml of acetic anhydride. The mixture is poured onto ice and subjected to extraction with dichloromethane. The organic extracts are washed in succession with saturated sodium bicarbonate solution and water, clarified over anhydrous sodium sulphate and filtered. Evaporation of the filtrate in vacuo yields 13.3 g of oil. The crude product obtained from two identical batches is subjected to flash chromatography on silica gel with toluene/ethyl acetate (ascending gradient) and gives 9.6 g of a mixture of 2-acetyl-4-(4-chlorophenyl)-buten-2-one and 3,5-diacetyl-4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran. Rechromatography over 700 g of silica gel using toluene and toluene/ethyl acetate = 20:1 gives 4.1 g of uniform product. m.p.: 86-88°C (cap.) (from dichloromethane/petroleum ether). Rf: 0.20 (toluene/ethyl acetate = 10:1). C17H17C103 Calc. C: 67.00%; H: 5.62% (304.8) Found C: 66.9%; H: 5.77% 'H-NMR (CDClj): 6 = 7.27-7.15 m (4, aromatic protons), 4.88 s (1, C4-H), 2.32 s (6, C3-COOCHj and C5-COOCH3), and 2.21 ppm s (C2-CH3 and C6-CH3).>. Lft-ArTM fi'j rwi'nitta^QUatffay 29 914 5 - 15 - Example 3 Dimethyl 4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran-dicarboxylate CI h3c-02c h3c O' XH3 co2ch3 a) 13.9 g (0.12 mol) of methyl acetoacetate and 7.0 g (0.05 mol) of 4-chlorobenzaldehyde are introduced with stirring at 25°C into a mixture of 9.6 ml of acetic anhydride and 6.8 g (0.05 mol) of anhydrous zinc chloride. With a temperature rise (to about b0°C) a pale yellow solution is obtained which is heated for 8 h at 60-65°C 3 times. The reaction mixture is worked up by introducing it into 200 ml of ice water and subjecting the mixture to extraction with dichloromethane. The organic phase is washed in succession with water, saturated sodium bicarbonate solution and again with water, clarified over anhydrous sodium sulphate and filtered, and the filtrate is evaporated in vacuo. The residue (18.8 g) is chromatographed over silica gel (1650 g) with toluene/ethyl acetate = 25:1, and yields 9.8 g (58%) of uniform pyran and 1.2 g of a mixture comprising equal parts of pyran and methyl 2-acetyl-3-(4-chlorophenyl)acrylate. Crystallization of the main fraction from petroleum ether/diethyl ether yields colourless crystals of m.p. 85-86°C. b) The title compound can be prepared analogously by reacting 17.4 g (0.11 mol) of methyl 3-acetoxycrotonate, 6.8 g of zinc chloride and 7 g (0.05 mol) of 4-chlorobenzaldehyde. After aqueous work-up, 14.9 g of crude product are obtained which is separated using silica gel and yields 10.5 g of uniform pyran. Lo i\ i3Hh*^^gPPH?terF€oBHtrw8' 29 91-0 - 16 Rf (toluene/ethyl acetate = 10:1): 0.41 CI7H17C105 Calc. C: 60.63%; H: 5.09% (336.8) Found C: 60.6%; H: 5.20% 'H-NMR (CDC13): 5 = 7.22-7.14 m (4, aromatic protons), 4.74 s (1, C4-H), 3.64 s (6, C3-COOCH3 and C5-COOCH3), and 2.36 ppm s (6, C2-CH3 and C6-CH3). Example 4 Methyl ethyl 4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran-dicarboxylate h5c2-o2c co2ch3 * A mixture of 9.5 g (0.04 mol) of methyl 2-acetyl-3-(4-chlorophenyl)acrylate, 5.7 g 10 (0.044 mol) of ethyl acetoacetate, 5.4 g (0.04 mol) of anhydrous zinc chloride and 7.5 ml of acetic anhydride is stirred for 8 h at 60-65°C 3 times. 4.0 ml of glacial acetic acid are added to the mixture, and stirring for 8 h at 60-65°C 3 times is repeated, After working up as described above, the crude product (15.9 g) is chrorr.atographed over 2000 g of silica gel using toluene. 5.3 g (30%) of crystalline pyran are obtained, m.p.: 15 67-69°C (from petroleum ether). Rf (toluene/ethyl acetate = 10:1): 0.53 'H-NMR (CDC13): 6 = 7.22-7.14 m (4, aromatic protons), 4.73 s (1, C4-H), 4.09 2 qu (2, C3-COOCH,-), 3.64 s (3, C5-COOCH3), 2.36 s (6, C2-CH3 and C6-CH3) and 1.20 ppm t (3, C3-COOCH2-CH3). - 17- Example 5 Methyl 5-acetyl-2,6-dimethyl-4-(4-chloro-3-trifluoromethyl)-4H-pyran-3-carboxylate CI 10 g (32.6 mmol) of methyl 2-acetyl-3-(4-chloro-3-trifluoromethylphenyl) acrylate and 5 10 g (97.8 mmol) of 2,4-pentanedione are stirred with 8.4 g of ZnCl2 in 20 ml of acetic anhydride at 60°C for 3 hours. After aqueous work-up and chromatography, 2.83 g of the title compound are obtained. Melting point: 96°C (petroleum ether) NMR (CDClj): 2.20 (s,3H), 2.36 (s,6H), 3.69 (s,3H), 4.82 (s,lH), 7.48 (m,2H), 10 7.51 (s,lH). ClgH,g04F3Cl (388.77): Calc.: C: 5 5 .61 % K 4.15 % 0: 16.46 % Found: C: 5 5.55 % H 4 .17 £ 0:16.32% In addition, Example 5 is obtained as a by-product of the synthesis of Example 32. The compounds listed in Tables 1 and 2 are prepared in analogy to the above Examples 15 1-5: 5 10 15 20 Ex.No. m.p. (°Q (cap.) R, (solv.) R1 R1 D 6 74-5 0.44 (a) -oc2h5 -ocjh, h 7 84-5 0.44 (a) -ocjhj -oc5h5 4-ochj 8 89 0.45 (a) -oc2h5 -oc,h, 3-noj 9 80 0.42 (a) -oc2h5 -oc,h5 2-ochj 10 99 0.49 (a) -oc,h5 -oc2h5 4-sch3 11 90 0.36 (a) -OCHj -ochj 2-OCHj 12 106 0.43 (a) -oc2h5 -oc,hs 4-oh 13 103-4 0.50 (a) -OCHj -och, 3,4-Cl, 14 81-2 0.62 (b) -och, -och, 3-chj 15 64-5 0.46 (a) -oc2h5 -oc,hs 4-CI 16 oil 200/0.01 mbar 0.33 (a) -och3 -och, 3-coochj 17 105-9 0.42 (a) -OCHj -och, 4-c6h5 18 122-6 0.46 (a) "OCHj -och, 2-chj 19 80-3 0.35 (a) -OCHj -och, 3-c1 20 62-4 0.41(a) -OCHj -och, h 21 73-6 0.41 (a) -och, -och, 4-f 22 68-9 0.47 (a) -OCHj -och, 3,4-f2 23 85-6 0.30 (a) -och, -och, 3-ocochj 24 45-6 0.51 (a) -0-n-C3H7 -O-n-CjH, 4-ci 25 51-3 0.56 (a) -0-n-C,H, -0-n-C4H, 4-ci Ltf A*^n lo^ruiuig ffCP uiiu lea -19 - / K i ft*-'* 10 Ex.No. m.p. (°Q (cap.) Rf (solv.) R1 R1 D 26 88-9 0.46 (A) -ocJhJ -ocjhj 2,3-Cl2 27 98-100 0.40 (A) -och, och, 2,3-Clj 28 67-9 0.53 (A) -OCHj -OC2h5 4-Cl 29 105-9 0.40 (A) -ochj -OCHj 4-C6hj 30 90 0.64 A) -och, -och, 4-CF, 31 69 0.55 (A) -och, -och, 3-cf, 32 81.5 0.41 (A) -CH, -och, 3-CF, 33 120 0.53 (A) -och, -och, 4-Cl, 3-CF, 34 96 0.41 (A) -CH, -och, 4-Cl, 3-CF, 35 86 0.29 (A) -CH, -CH, 4-Cl, 3-CF, 36 106 0.32 (A) -CH, -CH, (3,4.5)-F, 37 50 0.27 (A) -CH, 1 o ac 4-CF, 38 91 0.31 (A) -CH, -CH, 3-CF, Table 2: 15 H3C02C .C02CH3 h3c o ch3 Ex. No. A m.p. (°Q Rf (solv.) 39 O 68-70 0.49(A) 40 a-Naphthyl 127-9 0.40 (A) Ff solv.: A: Toluene/ethyl acetate = 10:1 Lw A 31 Utt'Iuiiim Couutik-J1 299145 -20- Examnlc 41 5-Acetyl-4-(4-chloro-3-trifluoromethylphenyl)-2,6-dimethyl-4H-pyran-3-carboximide Preliminaiy stage a) 5 1.01 g (2.57 mmol) are dissolved in 10 ml of THF, 10 ml of MeOH and 10 ml of IN NaOH are added, and the mixture is stirred at RT overnight. The solvent is then removed by distillation and the residue is partitioned between water and Et,0. The aqueous phase is adjusted to a pH of 5 and the precipitate which forms is filtered off with suction and washed. 432 mg (45% of theory) are obtained of a colourless powder 10 which has sufficient purity for subsequent reactions. Preliminaiy stage b) 1 g of the above acid is dissolved in 10 ml of SOCl2 and the solution is refluxed for 1.5 h. The reagent is then removed by distillation and the residue is taken up in 50 ml 15 10 ml of 25% strength ammonia water are added, with cooling, and the mixture is stirred at RT for 30 min. It is then concentrated and the residue is partitioned between ethyl acetate (AcOEt) and H20. Following extraction (AcOEt), drying (MgS04) and concentration are carried out. CI of THF. The crude product is purified by chromatography on silica gel (petroleum ether/AcOH, Lto A 31 1C1 rm'aian Cowntwea. Hi f JB - 21 - gradient). 319 mg, 31%, of a pale brown powder are obtained. Melting point: 129°C Re = 0.65 NMR: (CDC13 200 MHz): 2.18 (s, 3H); 2.24 (s, 3H); 2.35 (s, 3H); 4.82 (s, 1H); 5.10 -5 5.40 (m, br, 2H) and 7.31 - 7.52 ppm (m, 3H). Examples 42 and 43 4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran-3,5-dicarboxylic acid 3-methyl ester 5-N-methylamide and N,Nf-dimethyl-4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran-3,5-dicarboxamide 10 MeOOC (42) and H3Cs (43) 15 2.0 ml of trimethylaluminium solution (5 m in n-hexane) are introduced slowly under argon at 5°C into a suspension of 1.35 g (20 mmol) of methylammonium chloride in 20 ml of absolute toluene. The temperature is allowed to rise to 25°C, the mixture is stirred for 1 to 2 hours until the evolution of gas has reached an end, and a clear be-A«3>ULfiA»yoraign Coiui'iliiia - 22 - solution is obtained (1 m solution of the reagent). 2.0 g (6 mmol) of dimethyl 4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran-3,5-dicarboxylate in 60 ml of absolute toluene are added dropwise at 25°C under argon to the resulting solution of the reagent (20 mmol). After heating at 80°C for 12 hours (TLC monitoring 5 of the degree of conversion), the mixture is cooled to 25°C and acidified carefully with 5% strength aqueous hydrochloric acid. The organic phase is separated off and the aqueous phase is subjected to extraction 3 times with ethyl acetate. The combined organic phases are washed with water until neutral, dried over sodium sulphate and filtered, and the filtrate is concentrated in vacuo. The crude product (1.5 g) is separated 10 over silica gel using toluene/ethyl acetate/methanol (gradient) and yields 0.1 g of starting material, 0.7 g of the mono-N-methylamide and 0.7 g of the bis-N-methylamide. 4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran-3,5-dicarboxylic acid 3-methyl ester 5-N-methylamide (Example 42) 15 Melting point: 163-165°C (cap.) (from dichloromethane/petroleum ether), Rf (toluene/ethyl acetate 3:1): 0.18 C17H18C1N04 (335.8) Calc. C 60.81% H 5.40% N 4.17% Found 60.6, 5.36, 4.23 NMR (CDC13): 2.20 (s, 3H), 2.30 (s, 3H), 2.70 (d, 6H), 3.60 (s, 3H), 4.55 (s, 20 1H), 5.20 (br, s, 1H) and 7.20 - 7.30 ppm (m, 4H). N,N'-dimethyl-4-(4-chlorophenyl)-2,6-dimethyl-4H-pyran-3,5-dicarboxamide (Example 43) Melting point: 256-259°C (cap.) (from ethyl acetate), Rf (ethyl acetate): 0.13 145 ■Li A 31 164-ruiumi Ctmntrtes - 23 - CI7H)8C1N04 Calc. C 60.9% H 5.70% N 8.66 % (334.8) Found: 60.99, 5.72, 8.37 NMR (CDC13): 2.13 (s, 6H), 2.70 (d, 6H), 4.50 (s, 1H), 5.30 (br, s, 2H), and 7.20 - 7.35 ppm (m, 4H). 5 The Examples specified in the table are prepared in analogy to the abovementioned procedures of Examples 41 to 43. </div>

Claims

1. Ex.No. A R2 m.p. Rr 44 45 '^r nh2 OCHj >220° 133° 0.33 (AcOEt) 0.74 (AcOEt) 46 41 (yT°P' nh2 och3 >220° 154° 0.35 (AcOEt) 0.89 (AcOEt) 47 48 9" nh2 och3 210°C 142.5 0.55 (AcOEt) 0.94 (AcOEt) 49 50 Y' nh2 och3 >220° 167.5° 0.39 (AcOEt) 0.8 (AcOEt) *t98,^f^t,4^4^gpgTgTr"CotnnffB^™" ^ jj;-25 -;WHAT WE CLAIM IS:;1. Substituted 4H-pyrans of the general formula;R1-OC^ .CO-R2;TjC (I>;r4^^O/^R3;in which;5 A represents cycloalkyl having 3 to 6 carbon atoms or represents straight-chain or branched alkyl having up to 8 carbon atoms, or represents aryl having 6 to 10 carbon atoms or represents pyridyl, which are optionally substituted up to 3 times by identical or different 10 substituents consisting of nitro, hydroxyl, carboxyl, cyano, aryl having;6 to 10 carbon atoms, halogen, cycloalkyl having 3 to 6 carbon atoms, trifluoromethyl or by straight-chain or branched alkyl, alkoxycarbonyl, alkylthio or alkoxy having in each case up to 6 carbon atoms, or by a group of the formula -O-CO-R5,;15 in which;R5 denotes straight-chain or branched alkyl having up to 6 carbon atoms,;20;R1 and R2 are identical or different and represent hydrogen, amino or represent straight-chain or branched alkyl, alkoxy or alkylamino having in each case up to 8 carbon atoms,;b»A 31 161 ForaiEin^»ftw^a8^»;-26- cyv i q:;R3 and R4 are identical or different and represent straight-chain or branched alkyl or acyl having in each case up to 6 carbon atoms,;and salts thereof,;5 with the exception of 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-;diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and 3,5-diethoxy carbonyl-2,4,6-trimethyl-4H-pyran.;

2. Substituted 4H-pyrans of the formula (I) according to Claim 1;in which;10 A represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, or represents straight-chain or branched alkyl having up to 6 carbon atoms,;or represents phenyl, naphthyl or pyridyl which are optionally substituted up to 3 times by identical or different substituents consisting of nitro, 15 cyano, fluoro, chloro, bromo, iodo, phenyl, naphthyl, trifluoromethyl,;hydroxyl, carboxyl, cyclopropyl, cyclopentyl, cyclohexyl or by straight-chain or branched alkyl, alkoxy carbonyl, alkylthio or alkoxy having in each case up to 4 carbon atoms, or by a group of the formula -O-CO-R5;in which;20 R5 denotes straight-chain or branched alkyl having up to 4 carbon atoms,;R1 and R2 are identical or different and;- 27 -;represent hydrogen, amino or represent straight-chain or branched alkyl, alkoxy or alkylamino having in each case up to 6 carbon atoms,;R3 and R4 are identical or different and represent straight-chain or branched alkyl or acyl having in each case up to 4 carbon atoms,;and salts thereof,;with the exception of 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and ?,5-diethoxycarbonyl-2,4,6-trimethyl-4H-pyran.;Substituted 4H-pyrans of the formula (I) according to Claim 1 in which;A represents cyclopropyl, cyclohexyl or represents straight-chain or branched alkyl having, up to 4 carbon atoms, or represents naphthyl or phenyl which are optionally substituted up to 3 times by identical or different substituents consisting of nitro, cyano, fluoro, chloro, bromo, iodo, phenyl, naphthyl, hydroxyl, carboxyl, cyclopropyl, cyclopentyl, cyclohexyl, trifluoromethyl, or by straight-chain or branched alkyl, alkoxycarbonyl, alkyltliio or alkoxy having in each case up to 4 carbon atoms, or by a group of the formula -O-CO-R5;in which;R5 denotes straight-chain or branched alkyl having up to 4 carbon atoms,;- 28 -;R1 and R2 are identical or different and represent hydrogen, amino or represent straight-chain or branched alkyl, alkoxy or alkylamino having in each case up to 4 carbon atoms,;R3 and R4 are identical or different and represent straight-chain or branched alkyl or acyl having in each case up to 4 carbon atoms,;and salts thereof,;with the exception of 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and 3,5-diethoxycarbonyl-2,4,6-trimethyl-4H-pyran.;4. Substituted 4H-pyrans according to Claim 1 to 3 for use as medicaments.;5. 3,5-Diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and 3,5-diethoxycarbonyl-2.4,6-trimethyl-4H-pyran for use as medicaments.;6. Process for the preparation of substituted 4H-pyrans according to Claim 1 to 3, characterized in that;[A] aldehydes of the general formula (II);A-CHO;(II);in which;A has the meaning given above are reacted with compounds of the general formula (III);^4^wqgn*eroTTtr ICS 199145 -29- or O O R8^S^A.R7 (HI) in which R6 embraces the meanings of R1 and R2 given above in each case and R7 embraces the meanings of R3 and R4 given above, [B] ylidene compounds of the general formula (IV) A R2-OC (IV) R3 in which 10 A, R2 and R3 have the meanings given above, are reacted with compounds of the general formula (Ilia) or (Illb) O O O I (Ilia) o (IHb) R4^ ^R1 in which R1 and R4 have the meanings given above and D together with the CO group, forms an electron-attracting, activated radical, with D representing for example hydrogen, trifuoromethyl, phenyl or Cj-C4-alkyl, preferably methyl, in inert solvents in the presence of auxiliaries and/or in the presence of a dehydrating agent, and, in the case of the compounds of the general formula (I) in which R'/R2 represent amino and/or alkylamino, the corresponding acids are first of all prepared by hydrolysis from the esters, are converted into the carbonyl chlorides by transesterification, for example with thionyl chloride, and in a final step are reacted with ammonia or alkylamines. Medicaments comprising at least one substituted 4H-pyran according to Claim 1 to

3. Medicaments according to Claim 7 for treating disorders of the central nervous system. Use of 4H-pyrans according to Claim 1 to 3 for the production of medicaments. Use of 4H-pyrans according to Claim 1 to 3 for the production of medicaments for the treatment of degenerative CNS disorders. Use of 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6- 29 9115, -31 - dimethyl-4-phenyl-4H-pyran and 3,5-diethoxycarbonyl-2,4,6-trimethyl-4H-pyran for the production of medicaments.

12. Use of 3,5-diacetyl-2,4,6-trimethyl-4H-pyran, 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyl-4H-pyran and 3,5-diethoxycarbonyl-2,4,6-trimethyl-4H-pyran for the production of medicaments for the treatment of degenerative CNS disorders.

13. Substituted 4H-pyrans of the general formula (I) according to claim 1 substantially as herein described or exemplified,

14. A process according to claim 6 substantially as herein described or exemplified.

15. A medicament according to claim 7 substantially as herein described or exemplified.

16. Use according to any one of claims 9-12 substantially as herein described or exemplified. RECEIVED Intellectual Property Office 3 0 JAN 1998 END OF CLAIMS of New Zealand